Nuvation Bio Inc.
For the period ended Sep 30, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 4, 2026
NUVB$4.20-3.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
(Unaudited, in thousands, except per share data)
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Revenue: | ||||
| Product revenue, net | $27,457 | $7,723 | $69,159 | $8,961 |
| Collaboration and license agreements revenue | 17,494 | 5,397 | 90,707 | 12,076 |
| Total revenue | 44,951 | 13,120 | 159,866 | 21,037 |
| Costs and expenses: | ||||
| Cost of sales | 2,115 | 335 | 3,401 | 507 |
| Cost of collaboration and license agreements revenue | 9,814 | 3,014 | 23,990 | 7,512 |
| Research and development | 32,679 | 28,846 | 98,387 | 80,809 |
| Selling, general and administrative | 42,553 | 37,359 | 123,453 | 111,236 |
| Total costs and expenses | 87,161 | 69,554 | 249,231 | 200,064 |
| Loss from operations | (42,210) | (56,434) | (89,365) | (179,027) |
| Other income (expense): | ||||
| Interest income | 6,157 | 6,033 | 15,861 | 16,134 |
| Interest expense | (6,116) | (6,534) | (19,583) | (7,009) |
| Investment advisory fees | (171) | (171) | (550) | (556) |
| Loss on debt extinguishment | — | — | (9,472) | — |
| Change in fair value of warrant liability | — | 612 | 2,865 | 315 |
| Realized (loss) gain on marketable securities | (13) | — | 4 | 2 |
| Net gain (loss) on disposal of fixed assets | — | 4 | 1 | (30) |
| Other income | 454 | 698 | 897 | 2,136 |
| Total other income (expense), net | 311 | 642 | (9,977) | 10,992 |
| Loss before income taxes | (41,899) | (55,792) | (99,342) | (168,035) |
| Provision for income taxes | — | — | — | — |
| Net loss | $(41,899) | $(55,792) | $(99,342) | $(168,035) |
| Net loss per share attributable to common stockholders, basic and diluted | $(0.12) | $(0.16) | $(0.28) | $(0.49) |
| Weighted average common shares outstanding, basic and diluted | 351,861 | 342,393 | 349,337 | 340,597 |
| Comprehensive loss: | ||||
| Net loss | $(41,899) | $(55,792) | $(99,342) | $(168,035) |
| Other comprehensive loss, net of taxes: | ||||
| Currency translation adjustment | (353) | (313) | (1,092) | (495) |
| Change in unrealized (loss) gain on available-for-sale securities | (1,652) | 501 | (3,337) | (217) |
| Comprehensive loss | $(43,904) | $(55,604) | $(103,771) | $(168,747) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.